Compare Boston Scientific Corporation (BSX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs RLX Technology Inc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while RLX Technology Inc trades at $1.98 (market cap $2.42B). The key difference: Boston Scientific Corporation is far larger — about 27.4× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | RLX | |
|---|---|---|
Market Cap | $66.37B | $2.42B |
Sector | Health | Technology |
52-Week High | $108.14 | $2.73 |
52-Week Low | $42.63 | $1.79 |
Enterprise Value | $75.94B | $1.05B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
RLX Technology trades at $1.97, up 1.03% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. RLX maintains strong profitability with a 22.47% net income margin and is debt-free with substantial cash flow from operations.
Outlook is mixed: strong fundamentals and industry growth potential are offset by recent earnings misses and a single analyst hold rating. Key risks include regulatory scrutiny in the vaping sector and execution challenges in global markets. The stock presents a value opportunity but requires monitoring of earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
